Simple HealthKit Raises $8M to Transform Health Diagnostics and Follow-Up Care; Expands Portfolio to Include Solutions for Sexual Health, Tripledemic
1 month ago
GlobeNewswire
FREMONT, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Simple HealthKit, addressing health inequity with the first human-centric, end-to-end healthcare platform that builds and delivers diagnostics, treatment and follow-up care for all, announced today that it has raised $8M in Series A funding led by Initialized Capital with participation from seed investors Kleiner Perkins, Kapor Capital and Quest Venture Partners to transform health diagnostics and follow-up care. This brings Simple HealthKit’s total funding to date to $12M.
The company also has expanded its portfolio of solutions to include diagnostics for sexual health, chronic conditions such as diabetes, and the current tripledemic (COVID-19, RSV and Flu A/B) sweeping the U.S.
Founded by a diverse team of scientists, engineers, physicians and difference-makers, including CEO Dr. Sheena Menezes, Simple HealthKit has a mission to bring health equity to underserved markets. It starts with reliable diagnostics (at-home, in-clinic or at-pharmacy) and fast results, providing immediate next steps for consultation and treatment if a person tests positive. The company provides a complete, omnichannel healthcare infrastructure from testing to telehealth and medication. Simple HealthKit’s infrastructure can plug into any organization's workflow via an open-ended API or HL7. The company operates its own CLIA-certified, CAP-accredited labs and returns results within 24 hours to speed time to treatment.
"Simple HealthKit is transforming traditional diagnostics with a human-centric approach, providing accessible testing tools in tandem with thoughtful follow-up care," said Garry Tan, Partner and Founder at Initialized, President and CEO of Y Combinator, and Simple HealthKit board member. "We believe this approach to diagnostics-as-a-service will be especially impactful in underserved markets where time and cost are often factors in whether or not people pursue care."
“The ability to build reliable and affordable health diagnostic products is what attracted Kleiner Perkins to lead Simple HealthKit’s seed round, and why we participated in this new round,” said Mamoon Hamid, Partner at Kleiner Perkins and Simple HealthKit board member. “We have tremendous respect for Dr. Menezes and the Simple HealthKit team, and all they have accomplished. This market is evolving rapidly, and Simple HealthKit has managed to both stay ahead of it and stay true to their mission.”
“I was raised in India and Kuwait, and saw hardships and health disparities at an early age. When I emigrated to the U.S. as an adult, I was shocked to see those disparities existed here too,” said Sheena Menezes, Ph.D. “Healthcare should not be a privilege, it is a basic right. We founded Simple HealthKit to address inequities for the most common conditions plaguing all populations. We focus on developing accurate diagnostics and combining them with follow-up care, in a way that’s affordable, accessible and most of all helpful. It’s not easy, but it’s so important.”
Simple HealthKit made the decision to expand to sexual health, diabetes and tripledemic diagnostics due to the devastating effects these conditions currently have in the U.S. For example, 1 in 2 sexually active people will contract an STD/STI by age 25, and many are asymptomatic and unaware. This can lead to dire consequences: 10-15% of women with untreated chlamydia for instance will develop PID, a leading cause of infertility. The current tripledemic – defined as Covid, the flu and RSV – is spreading quickly in the U.S. with flu activity trending 10x higher than previous years.
Simple HealthKit’s test for sexual health and respiratory illness are available now at the company’s web site. At-home tests may be covered by HSA/ FSA programs, while in-clinic and at-pharmacy tests are typically reimbursable through health insurance. Later this year, these tests and more will be available via leading retailers, both in-store and online.
“Simple HealthKit builds solutions for high-need and high-impact population health challenges,” said Dr. Menezes. “This funding will help us further invest in innovation and accelerate our efforts to reach more people faster. We’re excited about the future and grateful to Initialized Capital, Kleiner Perkins, Kapor Capital and all our investors for their ongoing support.”
About Simple HealthKit
Simple HealthKit is the first and only human-centric, end-to-end healthcare platform that builds and delivers diagnostics, treatment and follow-up care for all. Created by people who believe world-class care is a right, not a privilege, Simple HealthKit addresses high-need and high-impact health challenges in all communities. The company offers high-quality, accessible, and affordable solutions for at-home or in-clinic diagnostics for sexual wellness, respiratory health, chronic conditions, and more. Simple HealthKit is working with leading retailers, pharmacies, educational institutions, employers, and public health organizations to bring health equity and world-class care to all communities and empower people with the information they need to lead healthier lives. Learn more at https://www.simplehealthkit.com/
Media contact:
Kerry Metzdorf
Big Swing
978-609-0766
[email protected]
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d04a23f4-1075-41f6-887c-c54c20ae7295
Continue reading...
Read On "GlobeNewswire" More News On "GlobeNewswire"
Hound Labs Names Debkishore Mitra as Chief Technology Officer
FREMONT, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Hound Labs, Inc., the leader in ultra-sensitive, automated, and analytical breath technologies and creator of the HOUND® CANNABIS BREATHALYZER,1 welcomes Debkishore (Deb) Mitra as its Chief Technology Officer (CTO). In his role, Mitra will lead the company’s research and development department and oversee the architecture, design, scientific testing, commercialization, and expansion of Hound Labs’ product offerings. Mitra will partner with the manufacturing team to ramp production of the HOUND® CANNABIS BREATHALYZER in spring 2023. For more information about the HOUND® CANNABIS BREATHALYZER and to reserve a shipping window, contact the Hound Labs sales team. Dr. Mike Lynn, emergency room physician, deputy sheriff (reserve), and former venture capitalist, co-founded Hound Labs, Inc. in 2014.
1 month ago
GlobeNewswire
EverestLabs Named as a Finalist in the Prestigious 2023 Edison Awards™
FREMONT, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- EverestLabs , developer of the first AI-enabled operating system for material recycling facilities (MRFs), today announced it has been named a finalist in the 2023 Edison Awards. The Edison Awards™, named after the American inventor Thomas Alva Edison, recognizes some of the most innovative products and business leaders in the world with past winners including Steve Jobs, Elon Musk, General Motors and Genentech. “We are honored to be named a finalist in The Edison Awards,” said JD Ambati, founder and CEO at EverestLabs. Gold, Silver and Bronze winners will be announced at the Edison Awards Gala on Thursday, April 20, 2023 in Fort Myers, Florida. About The Edison Awards:Established in 1987, the Edison Awards is a program conducted by Edison Universe, a non-profit 501(c)(3) organization dedicated to fostering future innovators.
1 month ago
GlobeNewswire
Enphase Energy and Lumio Expand Solar Technology Leadership Across the United States
Enphase® Energy Systems with IQ Batteries and the revolutionary IQ8 Microinverters, the industry’s first microgrid-forming microinverters launched late last year , offer homeowners even greater resilience than ever before. The strategic relationship with Lumio will amplify the impact and distribution of Enphase Energy Systems — providing homeowners more access to reliable, sustainable, and grid-independent power sources. Enphase IQ8 solar microinverters are built to last and come with a 25-year limited warranty. © 2023 Enphase Energy, Inc. All rights reserved. Enphase, the "e" logo, IQ, IQ8, Enphase Energy System, Sunlight Jump Start, IQ Batteries, and certain other names and marks are trademarks of Enphase Energy, Inc. Other names are for informational purposes and may be trademarks of their respective owners.
1 month ago
GlobeNewswire
Enphase Energy Demonstrates Bidirectional Electric Vehicle Charger Technology
This product will leverage the power of grid-forming IQ8™ Microinverters and Ensemble™ energy management technology to seamlessly integrate into Enphase® home energy systems. In addition, Enphase’s bidirectional EV charger is expected to work with most EVs that support standards such as CCS (Combined Charging System) and CHAdeMO (a Japanese charging standard). allows the EV battery to share energy with the grid to help relieve the strain on electric utilities during times of peak energy demand. “The Enphase bidirectional EV charger is the next step on our roadmap to building a solar-powered, all-in-one home energy system that further unlocks electrification, resilience, savings, and control for homeowners,” said Mohammad Alkuran, Ph.D., senior director of systems engineering at Enphase Energy. Enphase, the "e" logo, Ensemble, Enphase Energy System, IQ, IQ8, IQ Batteries, and certain other names and marks are trademarks of Enphase Energy, Inc. Other names are for informational purposes and may be trademarks of their respective owners.
1 month ago
GlobeNewswire
Rhinitis Pipeline Appears Robust With 32+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
New York, USA, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Rhinitis Pipeline Appears Robust With 32+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightThe prevalence of rhinitis, both allergic and non-allergic, are on the rise. DelveInsight’s 'Rhinitis Pipeline Insight – 2023' report provides comprehensive global coverage of available, marketed, and pipeline rhinitis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the rhinitis pipeline domain. Key Takeaways from the Rhinitis Pipeline ReportDelveInsight’s rhinitis pipeline report depicts a robust space with 32+ active players working to develop 35+ pipeline therapies for rhinitis treatment. Allergic Rhinitis Epidemiology ForecastAllergic Rhinitis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted allergic rhinitis epidemiology in the 7MM. Seasonal Allergic Rhinitis PipelineSeasonal Allergic Rhinitis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key seasonal allergic rhinitis companies, including Advagene Biopharma, AOBiome LLC, H. Lundbeck A/S, CSPC ZhongQi Pharmaceutical, Inimmune, among others.
2 months ago
GlobeNewswire Press Release Distribution